What is Spyre Therapeutics Cash Flow from Investing?
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Sep. 2024, Spyre Therapeuticsspent$0.00 Mil on purchasing property, plant, equipment.
It gained$0.00 Mil from selling property, plant, and equipment.
It spent$0.00 Mil on purchasing business.
It gained$0.00 Mil from selling business.
It spent$35.05 Mil on purchasing investments.
It gained$77.79 Mil from selling investments.
It paid$0.00Mil for net Intangibles purchase and sale.
And it paid$0.00 Mil for other investing activities.
In all, Spyre Therapeuticsgained$42.74 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Sep. 2024.
Spyre Therapeutics Cash Flow from Investing Historical Data
The historical data trend for Spyre Therapeutics's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Spyre Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-218.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (NAS:SYRE) Cash Flow from Investing Explanation
Spyre Therapeutics's purchase of property, plant, equipment for the
three
months ended in Sep. 2024 was $0.00 Mil. It means Spyre Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Spyre Therapeutics's sale of property, plant, equipment for the
three
months ended in Sep. 2024 was $0.00 Mil. It means Spyre Therapeutics gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Spyre Therapeutics's purchase of business for the
three
months ended in Sep. 2024 was $0.00 Mil. It means Spyre Therapeutics spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Spyre Therapeutics's sale of business for the
three
months ended in Sep. 2024 was $0.00 Mil. It means Spyre Therapeutics gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Spyre Therapeutics's purchase of investment for the
three
months ended in Sep. 2024 was $-35.05 Mil. It means Spyre Therapeutics spent {stock_data.stock.currency_symbol}}35.05 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Spyre Therapeutics's sale of investment for the
three
months ended in Sep. 2024 was $77.79 Mil. It means Spyre Therapeutics gained $77.79 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Spyre Therapeutics's net Intangibles purchase and sale for the
three
months ended in Sep. 2024 was $0.00 Mil.
It means Spyre Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Spyre Therapeutics's cash from discontinued investing activities for the
three
months ended in Sep. 2024 was 0.00 Mil.
It means Spyre Therapeutics paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Spyre Therapeutics's cash from other investing activities for the
three
months ended in Sep. 2024 was $0.00 Mil.
It means Spyre Therapeutics paid $0.00 Mil for other investing activities.
Spyre Therapeutics Cash Flow from Investing Related Terms
Thank you for viewing the detailed overview of Spyre Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SYRE has been successfully added to your 